Testing an IOV-4001 infusion for advanced melanoma or lung cancer
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma (Stage IIIC/IIID/IV that can’t be removed) or advanced non-small-cell lung cancer (Stage III/IV that can’t be removed)
- Your prior treatment matches one of the study’s specific rules, including recent progress after certain immunotherapy medicines (anti–PD-1/PD-L1)
- You can do normal daily activities pretty well (ECOG 0 or 1)
- Doctors can find at least one spot of cancer that can be measured after a needed procedure for treatment planning
- Your heart (and sometimes lung) tests meet the trial’s safety limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OBX-115, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments.
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests an investigational cell therapy, IOV-5001, in adults with certain advanced cancers (lung, breast, colorectal, or head and neck). The therapy uses a patient's own immune cells to target the tumor, and the study aims to see if it can slow or stop cancer growth.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
This study is testing a new blood test called IOpener®-Melanoma to see if it can predict which patients with advanced melanoma will respond well to immunotherapy. The goal is to better match treatments to people who will benefit most.
Hear when a new Unresectable Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.